Eterna Therapeutics Files 8-K: Material Agreement, Equity Sales
Ticker: ERNAW · Form: 8-K · Filed: Apr 3, 2025 · CIK: 748592
| Field | Detail |
|---|---|
| Company | Eterna Therapeutics Inc. (ERNAW) |
| Form Type | 8-K |
| Filed Date | Apr 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, shareholder-nomination
Related Tickers: ETRN
TL;DR
ETRN filed an 8-K on 3/31/25 for material agreement, equity sales, and shareholder nominations.
AI Summary
Eterna Therapeutics Inc. filed an 8-K on April 3, 2025, reporting on events as of March 31, 2025. The filing indicates an entry into a material definitive agreement, unregistered sales of equity securities, and shareholder nominations. It also includes financial statements and exhibits.
Why It Matters
This 8-K filing signals significant corporate actions, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves unregistered sales of equity securities and shareholder nominations, which can introduce uncertainty and potential dilution.
Key Numbers
- 20250331 — Report Date (Earliest event date reported)
- 20250403 — Filing Date (Date the report was filed with the SEC)
Key Players & Entities
- Eterna Therapeutics Inc. (company) — Registrant
- Brooklyn ImmunoTherapeutics, Inc. (company) — Former Company Name
- NTN BUZZTIME INC (company) — Former Company Name
- NTN COMMUNICATIONS INC (company) — Former Company Name
- 001-11460 (dollar_amount) — SEC File Number
FAQ
What is the nature of the material definitive agreement entered into by Eterna Therapeutics Inc.?
The filing indicates an entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold unregistered?
The filing mentions 'Unregistered Sales of Equity Securities' as an item of disclosure, but does not specify the type or amount of securities sold.
What are the key details regarding the shareholder nominations?
The filing lists 'Shareholder Nominations Pursuant to Exchange Act Rule 14a-11' as an item, suggesting nominations have been made, but specific names or details are not in the provided text.
When did Eterna Therapeutics Inc. change its name from Brooklyn ImmunoTherapeutics, Inc.?
Eterna Therapeutics Inc. changed its name from Brooklyn ImmunoTherapeutics, Inc. on March 25, 2021.
What is the primary business of Eterna Therapeutics Inc.?
Eterna Therapeutics Inc. is classified under 'PHARMACEUTICAL PREPARATIONS' with SIC code 2834.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 3, 2025 regarding Eterna Therapeutics Inc. (ERNAW).